Vident Investment Advisory’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,144	Closed	-$217K	–	49
2023 Q2	$217K	Buy	+1,144	New	+$227K	0.01%	1025
2022 Q2	–	Sell	-12,161	Closed	-$1.98M	–	1274
2022 Q1	$1.98M	Buy	12,161 +5,136	+73%	+$782K	0.05%	457
2021 Q4	$1.19M	Sell	7,025 -4,255	-38%	-$791K	0.03%	643
2021 Q3	$2.13M	Buy	11,280 +889	+9%	+$167K	0.06%	372
2021 Q2	$1.76M	Sell	10,391 -1,206	-10%	-$177K	0.05%	460
2021 Q1	$1.64M	Buy	11,597 +651	+6%	+$98K	0.06%	467
2020 Q4	$1.42M	Buy	10,946 +873	+9%	+$117K	0.06%	427
2020 Q3	$1.47M	Sell	10,073 -289	-3%	-$41.1K	0.07%	374
2020 Q2	$1.53M	Buy	10,362 +7,603	+276%	+$1.02M	0.08%	302
2020 Q1	$300K	Buy	2,759 +366	+15%	+$42.2K	0.02%	684
2019 Q4	$276K	Sell	2,393 -1,756	-42%	-$175K	0.02%	649
2019 Q3	$334K	Sell	4,149 -1,321	-24%	-$105K	0.03%	422
2019 Q2	$397K	Sell	5,470 -3,422	-38%	-$263K	0.03%	396
2019 Q1	$831K	Buy	8,892 +1,528	+21%	+$128K	0.04%	450
2018 Q4	$537K	Sell	7,364 -170	-2%	-$13.1K	0.03%	564
2018 Q3	$659K	Sell	7,534 -89	-1%	-$8.95K	0.03%	595
2018 Q2	$751K	Buy	7,623 +3,157	+71%	+$313K	0.03%	510
2018 Q1	$429K	Buy	4,466 +2,400	+116%	+$309K	0.02%	683
2017 Q4	$262K	Buy	+2,066	New	+$260K	0.01%	722